Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [912]

Maintenance in NSCLC: Arguments against

Dr Benjamin Besse - Institut Gustave Roussy, Paris, France

Maintenance in NSCLC: Arguments against ( Dr Benjamin Besse - Institut Gustave Roussy, Paris, France )

We should use PDL1 and other biomarkers for selecting patients for immune...

Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK

We should use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Dr Mary O’Brien - The Royal Marsden NHS Foundation Trust, London, UK )

We should not use PDL1 and other biomarkers for selecting patients for immune...

Prof Gordon McVie - King's College London, London, UK

We should not use PDL1 and other biomarkers for selecting patients for immune checkpoint therapies ( Prof Gordon McVie - King's College London, London, UK )

Using PDL1 and other biomarkers in patient selection for immunology: Q & A

Dr O'Brien and Prof McVie

Using PDL1 and other biomarkers in patient selection for immunology: Q & A ( Dr O'Brien and Prof McVie )

Current standards of care in advanced NSCLC

Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada

Current standards of care in advanced NSCLC ( Dr Frances Shepherd - The Princess Margaret Cancer Centre, Toronto, Canada )

Imaging and novel PET tracers: Q & A

Dr Giulia Veronesi and Prof Tony Ng

Imaging and novel PET tracers: Q & A ( Dr Giulia Veronesi and Prof Tony Ng )

Imaging and novel PET tracers: The future

Prof Tony Ng - King's College London, London, UK

Imaging and novel PET tracers: The future ( Prof Tony Ng - King's College London, London, UK )

Imaging and novel PET tracers: State of the art

Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy

Imaging and novel PET tracers: State of the art ( Dr Giulia Veronesi - Humanitas Research Hospital, Milan, Italy )

Radiotherapy - what's new? Q & A

Dr David Landau and Prof Corinne Favire-Finn

Radiotherapy - what's new? Q & A ( Dr David Landau and Prof Corinne Favire-Finn )

Radiotherapy in lung cancer: Future directions

Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK

Radiotherapy in lung cancer: Future directions ( Dr David Landau - Guy's and St Thomas' NHS Trust, London, UK )

Radiotherapy in lung cancer: Current state of the art

Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK

Radiotherapy in lung cancer: Current state of the art ( Prof Corinne Faivre-Finn - Christie NHS Foundation Trust, Manchester, UK )

Metabolomics: Reversing drug resistance

Dr Olivier Pardo - Imperial College London, London, UK

Metabolomics: Reversing drug resistance ( Dr Olivier Pardo - Imperial College London, London, UK )

More from ecancer